Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04945733
Other study ID # CR109026
Secondary ID 61186372GIC2001
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 30, 2021
Est. completion date July 3, 2023

Study information

Verified date March 2024
Source Janssen Pharmaceutical K.K.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).


Recruitment information / eligibility

Status Terminated
Enrollment 62
Est. completion date July 3, 2023
Est. primary completion date July 3, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Participant must have histologically or cytologically confirmed gastric (including gastroesophageal junction [GEJ]) or esophageal cancer (EC) that is locally advanced, unresectable, or metastatic, and not eligible for curative treatment - Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. If only 1 measurable lesion exists, it may be used for the screening biopsy if the baseline tumor assessment scans are performed greater than or equal to (>=) 7 days after the biopsy - Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Gastric or GEJ Cancer Only - Must be refractory or ineligible to at least 2 prior lines of standard of care systemic therapy. Prior therapies must include fluoropyrimidine- and platinum-based chemotherapy. Participants with known human epidermal growth factor receptor (HER) 2 expression must have had HER2 targeting therapy as part of the prior therapy Esophageal Cancer Only - Must be refractory or intolerant to at least 1 prior line of systemic therapy. Prior therapies must include fluoropyrimidine-, and platinum-based chemotherapy (including chemoradiation therapy given as stage intravenous [IV] setting) Exclusion Criteria: - Participant has an uncontrolled illness, including but not limited to the following: diabetes; ongoing or active bacterial infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week before enrollment]), symptomatic viral infection, or any other clinically significant infection; active bleeding diathesis and psychiatric illness/social situation that would limit compliance with study requirements - Participant has received prior epidermal growth factor receptor (EGFR) or tyrosine-protein kinase mesenchymal-epithelial transition (cMet)-directed therapies - Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives whichever is longer or had radiation therapy within 4 weeks before the first administration of study treatment. For agents with long half-lives, the maximum required time since last dose is 28 days. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia or post-radiation skin changes [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement) - Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to the first administration of study treatment is eligible), history of leptomeningeal disease or spinal cord compression that has not been treated definitively with surgery or radiation. If brain metastases are diagnosed on screening imaging, the participant may be rescreened for eligibility after definitive treatment - Participant has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Esophageal cancer participants with history of completely resolved radiation pneumonitis (defined as radiographically stable for 3 months prior to enrollment without need of any treatment) may be enrolled

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amivantamab
Amivantamab will be administered intravenously.

Locations

Country Name City State
Japan National Cancer Center Hospital Chuo-Ku
Japan National Cancer Center Hospital East Kashiwa
Japan Saitama Cancer center Kitaadachi-gun
Japan Niigata Cancer Center Hospital Niigata
Japan Hokkaido University Hospital Sapporo-shi
Japan Tohoku University Hospital Sendai
Japan Osaka University Hospital Suita-shi
Japan The Cancer Institute Hospital of JFCR Tokyo
Japan Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo
Japan Yokohama City University Medical Center Yokohama

Sponsors (1)

Lead Sponsor Collaborator
Janssen Pharmaceutical K.K.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) ORR is defined as the percentage of participants who achieve either complete response (CR) or partial response (PR), determined by investigator assessment using response evaluation criteria in solid tumors (RECIST) version 1.1. Up to 1 year and 10 months
Secondary Disease Control Rate (DCR) DCR is defined as the percentage of participants achieving complete or partial response or stable disease for at least 6 weeks as defined by RECIST Version1.1. Up to 1 year and 10 months
Secondary Duration of Response (DOR) DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first. Up to 1 year and 10 months
Secondary Time to Response (TTR) TTR is defined as the time from the date of first amivantamab administration to the date of achieving objective response (CR or PR) by investigator assessment using RECIST Version 1.1 among participants who achieve objective response. Up to 1 year and 10 months
Secondary Progression-free Survival (PFS) PFS is defined as the time from first dose until the date of objective disease progression or death (by any cause in the absence of progression), whichever comes first, based on investigator assessment using RECIST Version 1.1. Up to 1 year and 10 months
Secondary Phase 2b: Overall Survival (OS) OS is defined as the time from the date of first dose until the date of death due to any cause. Up to 1 year and 10 months
Secondary Number of Participants with Adverse Events (AEs) An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Up to 1 year and 10 months
Secondary Maximum Serum Concentration (Cmax) of Amivantamab Cmax is defined as maximum concentration of amivantamab. Up to 1 year and 10 months
Secondary Time to Reach Maximum Concentration (Tmax) of Amivantamab Tmax is defined as time to reach maximum serum concentration of amivantamab. Up to 1 year and 10 months
Secondary Area Under the Serum Concentration-time Curve From t1 to t2 Time (AUC[t1-t2]) of Amivantamab AUC(t1-t2) is defined as the area under the serum concentration-time curve from time t1 to t2. Up to 1 year and 10 months
Secondary Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau) AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval. Up to 1 year and 10 months
Secondary Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration. Up to 1 year and 10 months
Secondary Accumulation Ratio (RA) of Amivantamab RA is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC [0-24]) value at steady state divided by AUC (0-24) value after first dose. Up to 1 year and 10 months
Secondary Number of Participants with Anti-Amivantamab Antibodies Serum samples will be collected to detect the anti-drug antibodies to amivantamab. The detection and characterization of antibodies to amivantamab will be performed using a validated immunoassay method. Up to 1 year and 10 months
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4